Richard E. Davis, M.D.

Peer-Reviewed Articles

1. Zhuang J, Shirazi F, Singh RK, Kuiatse I, Wang H, Lee HC, Berkova Z, Berger A, Hyer M, Chattopadhyay N, Syed S, Shi JQ, Yu J, Shinde V, Tirrell S, Jones RJ, Wang Z, Davis RE , Orlowski RZ. Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma. Blood 133(14):1572-1584, 2019. e-Pub 2019. PMID: 30737236.
2. Latha K, Yan J, Yang Y, Gressot LV, Kong LY, Manyam G, Ezhilarasan R, Wang Q, Sulman EP, Eric Davis R , Huang S, Fuller GN, Rao A, Heimberger AB, Li S, Rao G. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst 111(3):292-300, 2019. PMID: 29947810.
3. Piya S, Mu H, Bhattacharya S, Lorenzi PL, Davis RE, McQueen T, Ruvolo V, Baran N, Wang Z, Qian Y, Crews CM, Konopleva M, Ishizawa J, You MJ, Kantarjian H, Andreeff M, Borthakur G. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment. J Clin Invest 130, 2019. e-Pub 2019. PMID: 30829648.
4. Strati P, Lee ST, Teegavarupu P, Karri A, Anireddy S, Hagemeister FB, Romaguera J, Fayad LE, Rodriguez MA, Samaniego F, Fowler N, Westin J, Wang M, Lee HJ, Pinnix C, Gunther JR, Dabaja B, Feng L, Davis RE , Neelapu SS. Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma. Am J Hematol, 2019. e-Pub 2019. PMID: 30785215.
5. Yan J, Zhao Q, Gabrusiewicz K, Kong LY, Xia X, Wang J, Ott M, Xu J, Davis RE , Huo L, Rao G, Sun SC, Watowich SS, Heimberger AB, Li S. FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat Commun 10(1):448, 2019. e-Pub 2019. PMID: 30683885.
6. Ni H, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Hitoshi Y, Ansell SM, Treon SP, Thomas SK, Lee HC, Wang Z, Davis RE , Orlowski RZ. Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24(24):6408-6420, 2018. e-Pub 2018. PMID: 30126942.
7. Zhang X, Lee HC, Shirazi F, Baladandayuthapani V, Lin H, Kuiatse I, Wang H, Jones RJ, Berkova Z, Singh RK, Lu J, Qian Y, Raina K, Coleman KG, Crews CM, Li B, Wang H, Hailemichael Y, Thomas SK, Wang Z, Davis RE, Orlowski RZ. Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32(10):2224-2239, 2018. e-Pub 2018. PMID: 29581547.
8. Huang L, Malu S, McKenzie JA, Andrews MC, Talukder AH, Tieu T, Karpinets T, Haymaker C, Forget MA, Williams LJ, Wang Z, Mbofung RM, Wang ZQ, Davis RE , Lo RS, Wargo JA, Davies MA, Bernatchez C, Heffernan T, Amaria RN, Korkut A, Peng W, Roszik J, Lizée G, Woodman SE, Hwu P. The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. Clin Cancer Res 24(14):3366-3376, 2018. e-Pub 2018. PMID: 29496759.
9. McKenzie JA, Mbofung RM, Malu S, Zhang M, Ashkin E, Devi S, Williams L, Tieu T, Peng W, Pradeep S, Xu C, Zorro Manrique S, Liu C, Huang L, Chen Y, Forget MA, Haymaker C, Bernatchez C, Satani N, Muller F, Roszik J, Kalra A, Heffernan T, Sood A, Hu J, Amaria R, Davis RE , Hwu P. The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst 110(7):777-786, 2018. PMID: 29267866.
10. Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE , Rao A, Andreeff M. Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78(10):2721-2731, 2018. e-Pub 2018. PMID: 29490944.
11. Cascone T, McKenzie JA, Mbofung RM, Punt S, Wang Z, Xu C, Williams LJ, Wang Z, Bristow CA, Carugo A, Peoples MD, Li L, Karpinets T, Huang L, Malu S, Creasy C, Leahey SE, Chen J, Chen Y, Pelicano H, Bernatchez C, Gopal YNV, Heffernan TP, Hu J, Wang J, Amaria RN, Garraway LA, Huang P, Yang P, Wistuba II, Woodman SE, Roszik J, Davis RE , Davies MA, Heymach JV, Hwu P, Peng W. Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metab 27(5):977-987.e4, 2018. e-Pub 2018. PMID: 29628419.
12. Jin Y, Chen K, De Paepe A, Hellqvist E, Krstic AD, Metang L, Gustafsson C, Davis RE , Levy YM, Surapaneni R, Wallblom A, Nahi H, Mansson R, Lin YC. Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma. Blood 131(19):2138-2150, 2018. e-Pub 2018. PMID: 29519805.
13. Liu W, Chen J, Tamayo AT, Ruan C, Li L, Zhou S, Shen C, Young KH, Westin J, Davis RE , Hu S, Medeiros LJ, Ford RJ, Pham LV. Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma. Oncotarget 9(1):346-360, 2018. e-Pub 2017. PMID: 29416618.
14. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE , Medeiros LJ, Oki Y. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma. PLoS One 13(3):e0191461, 2018. e-Pub 2018. PMID: 29538376.
15. Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE , Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res 15(12):1692-1703, 2017. e-Pub 2017. PMID: 28835371.
16. Wang H, Baladandayuthapani V, Wang Z, Lin H, Berkova Z, Davis RE , Yang L, Orlowski RZ. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. Oncotarget 8(69):113858-113873, 2017. e-Pub 2017. PMID: 29371952.
17. Yang J, Liu Z, Liu H, He J, Yang J, Lin P, Wang Q, Du J, Ma W, Yin Z, Davis E , Orlowski RZ, Hou J, Yi Q. C-reactive protein promotes bone destruction in human myeloma through the CD32-p38 MAPK-Twist axis. Sci Signal 10(509), 2017. e-Pub 2017. PMID: 29233917.
18. Tu YS, He J, Liu H, Lee HC, Wang H, Ishizawa J, Allen JE, Andreeff M, Orlowski RZ, Davis RE , Yang J. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma. Neoplasia 19(10):772-780, 2017. e-Pub 2017. PMID: 28863346.
19. Mbofung RM, McKenzie JA, Malu S, Zhang M, Peng W, Liu C, Kuiatse I, Tieu T, Williams L, Devi S, Ashkin E, Xu C, Huang L, Zhang M, Talukder AH, Tripathi SC, Khong H, Satani N, Muller FL, Roszik J, Heffernan T, Allison JP, Lizee G, Hanash SM, Proia D, Amaria R, Davis RE , Hwu P. HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun 8(1):451, 2017. e-Pub 2017. PMID: 28878208.
20. Havranek O, Xu J, Köhrer S, Wang Z, Becker L, Comer JM, Henderson J, Ma W, Man Chun Ma J, Westin JR, Ghosh D, Shinners N, Sun L, Yi AF, Karri AR, Burger JA, Zal T, Davis RE . Tonic B-cell receptor signaling in diffuse large B-cell lymphoma. Blood 130(8):995-1006, 2017. e-Pub 2017. PMID: 28646116.
21. Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE , Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol 96(6):977-985, 2017. e-Pub 2017. PMID: 28337527.
22. Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, Kuiatse I, Gu D, Wang Z, Ma W, Lim J, O'Brien S, Keats J, Yang J, Davis RE , Orlowski RZ. RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. Br J Haematol 177(1):80-94, 2017. PMID: 28369725.
23. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE , Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2016. PMID: 27983760.
24. Kim E, Hurtz C, Koehrer S, Wang Z, Balasubramanian S, Chang BY, Müschen M, Davis RE , Burger JA. Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129(9):1155-1165, 2017. e-Pub 2016. PMID: 28031181.
25. Mathur R, Sehgal L, Havranek O, Köhrer S, Khashab T, Jain N, Burger JA, Neelapu SS, Davis RE, Samaniego F. Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs. Haematologica 102(2):373-380, 2017. e-Pub 2016. PMID: 27742770.
26. Battula VL, Le PM, Sun JC, Nguyen K, Yuan B, Zhou X, Sonnylal S, McQueen T, Ruvolo V, Michel KA, Ling X, Jacamo R, Shpall E, Wang Z, Rao A, Al-Atrash G, Konopleva M, Davis RE , Harrington MA, Cahill CW, Bueso-Ramos C, Andreeff M. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight 2(13), 2017. e-Pub 2017. PMID: 28679949.
27. Jacamo R, Davis RE , Ling X, Sonnylal S, Ma W, Zhang M, Ruvolo P, Ruvolo V, Wang RY, Lowe S, Zuber J, Kornblau SM, Konopleva M, Andreeff M. Tumor Trp53 status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget, 2017. e-Pub 2017. PMID: 28708600.
28. Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE , Nastoupil LJ. Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122(20):3145-3151, 2016. e-Pub 2016. PMID: 27351173.
29. Randhawa S, Cho BS, Ghosh D, Sivina M, Koehrer S, Müschen M, Peled A, Davis RE , Konopleva M, Burger JA. Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. Br J Haematol 174(3):425-36, 2016. e-Pub 2016. PMID: 27071778.
30. Liu H, Liu Z, Du J, He J, Lin P, Amini B, Starbuck MW, Novane N, Shah JJ, Davis RE , Hou J, Gagel RF, Yang J. Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma. Sci Transl Med 8(353):353ra113, 2016. PMID: 27559096.
31. Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, Ten Hacken E, Jäger U, Vanura K, O'Brien S, Thomas DA, Kantarjian H, Ghosh D, Wang Z, Zhang M, Ma W, Jumaa H, Debatin KM, Müschen M, Meyer LH, Davis RE , Burger JA. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia 30(6):1246-54, 2016. e-Pub 2016. PMID: 26847027.
32. Cheah CY, Chihara D, Ahmed M, Davis RE , Nastoupil LJ, Phansalkar K, Hagemeister FB, Fayad LE, Westin JR, Oki Y, Fanale MA, Romaguera JE, Wang ML, Lee H, Turturro F, Samaniego F, Rodriguez MA, Neelapu SS, Fowler NH. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era. Ann Oncol 27(5):895-901, 2016. e-Pub 2016. PMID: 26802151.
33. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DL, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE , Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell 29(5):639-52, 2016. e-Pub 2016. PMID: 27132469.
34. Benito J, Ramirez MS, Millward NZ, Velez J, Harutyunyan KG, Lu H, Shi YX, Matre P, Jacamo R, Ma H, Konoplev S, McQueen T, Volgin A, Protopopova M, Mu H, Lee J, Bhattacharya PK, Marszalek JR, Davis RE , Bankson JA, Cortes JE, Hart CP, Andreeff M, Konopleva M. Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models. Clin Cancer Res 22(7):1687-98, 2016. e-Pub 2015. PMID: 26603259.
35. Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Davis RE , Andreeff M. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta 1863(4):562-71, 2016. e-Pub 2015. PMID: 26704388.
36. Feldmeyer L, Ching G, Vin H, Ma W, Bansal V, Chitsazzadeh V, Jahan-Tigh R, Chu EY, Fuller P, Maiti S, Davis RE , Cooper LJ, Tsai KY. Differential T-cell subset representation in cutaneous squamous cell carcinoma arising in immunosuppressed versus immunocompetent individuals. Exp Dermatol 25(3):245-7, 2016. e-Pub 2015. PMID: 26475987.
37. Ishizawa J, Kojima K, Chachad D, Ruvolo P, Ruvolo V, Jacamo RO, Borthakur G, Mu H, Zeng Z, Tabe Y, Allen JE, Wang Z, Ma W, Lee HC, Orlowski R, Sarbassov dos D, Lorenzi PL, Huang X, Neelapu SS, McDonnell T, Miranda RN, Wang M, Kantarjian H, Konopleva M, Davis RE , Andreeff M. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies. Sci Signal 9(415):ra17, 2016. e-Pub 2016. PMID: 26884599.
38. Piya S, Kornblau SM, Ruvolo VR, Mu H, Ruvolo PP, McQueen T, Davis RE , Hail N, Kantarjian H, Andreeff M, Borthakur G. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood, 2016. e-Pub 2016. PMID: 27268264.
39. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE , Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov, 2016. e-Pub 2016. PMID: 27301722.
40. Matre P, Velez J, Jacamo R, Qi Y, Su X, Cai T, Chan SM, Lodi A, Sweeney SR, Ma H, Davis RE , Baran N, Haferlach T, Su X, Flores ER, Gonzalez D, Konoplev S, Samudio I, DiNardo C, Majeti R, Schimmer AD, Li W, Wang T, Tiziani S, Konopleva M. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. Oncotarget, 2016. e-Pub 2016. PMID: 27806325.
41. Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O'Brien S, Davis RE , Burger JA. CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. Br J Haematol 171(5):726-35, 2015. e-Pub 2015. PMID: 26358140.
42. Cho BS, Zeng Z, Mu H, Wang Z, Konoplev S, McQueen T, Protopopova M, Cortes J, Marszalek JR, Peng SB, Ma W, Davis RE, Thornton DE, Andreeff M, Konopleva M. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood 126(2):222-32, 2015. e-Pub 2015. PMID: 26031918.
43. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE , Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. PMID: 25863759.
44. Tabe Y, Kojima K, Yamamoto S, Sekihara K, Matsushita H, Davis RE , Wang Z, Ma W, Ishizawa J, Kazuno S, Kauffman M, Shacham S, Fujimura T, Ueno T, Miida T, Andreeff M. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. PLoS One 10(9):e0137210, 2015. e-Pub 2015. PMID: 26340096.
45. Voo KS, Foglietta M, Percivalle E, Chu F, Nattamai D, Harline M, Lee ST, Bover L, Lin HY, Baladandayuthapani V, Delgado D, Luong A, Davis RE , Kwak LW, Liu YJ, Neelapu SS. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 135(12):2834-46, 2014. e-Pub 2014. PMID: 24771328.
46. Li J, Kurasawa Y, Wang Y, Clise-Dwyer K, Klumpp SA, Liang H, Tailor RC, Raymond AC, Estrov Z, Brandt SJ, Davis RE , Zweidler-McKay P, Amin HM, Nagarajan L. A Requirement for Ssbp2 in Hematopoietic Stem Cell Maintenance and Stress Response. J Immunol 193(9):4654-62, 2014. e-Pub 2014. PMID: 25238756.
47. Fowler NH, Davis RE , Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15(12):1311-8, 2014. e-Pub 2014. PMID: 25439689.
48. Oki Y, Noorani M, Lin P, Davis RE , Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
49. Jacamo R, Chen Y, Wang Z, Ma W, Zhang M, Spaeth EL, Wang Y, Battula VL, Mak PY, Schallmoser K, Ruvolo P, Schober WD, Shpall EJ, Nguyen MH, Strunk D, Bueso-Ramos CE, Konoplev S, Davis RE , Konopleva M, Andreeff M. Reciprocal leukemia-stroma VCAM-1/VLA-4-dependent activation of NF-κB mediates chemoresistance. Blood 123(17):2691-702, 2014. e-Pub 2014. PMID: 24599548.
50. Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N, Romaguera J, Hagemeister F, Fanale M, Samaniego F, Feng L, Baladandayuthapani V, Wang Z, Ma W, Gao Y, Wallace M, Vence LM, Radvanyi L, Muzzafar T, Rotem-Yehudar R, Davis RE , Neelapu SS. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69-77, 2014. e-Pub 2013. PMID: 24332512.
51. Lu Y, Zhang M, Wang S, Hong B, Wang Z, Li H, Zheng Y, Yang J, Davis RE , Qian J, Hou J, Yi Q. p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun 5:4229, 2014. e-Pub 2014. PMID: 24957461.
52. Carter BZ, Mak DH, Wang Z, Ma W, Mak PY, Andreeff M, Davis RE . XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res 37(8):974-9, 2013. e-Pub 2013. PMID: 23669290.
53. Battula VL, Chen Y, Cabreira Mda G, Ruvolo V, Wang Z, Ma W, Konoplev S, Shpall E, Lyons K, Strunk D, Bueso-Ramos C, Davis RE , Konopleva M, Andreeff M. Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood 122(3):357-66, 2013. e-Pub 2013. PMID: 23741006.
54. Rawal S, Chu F, Zhang M, Park HJ, Nattamai D, Kannan S, Sharma R, Delgado D, Chou T, Lin HY, Baladandayuthapani V, Luong A, Vega F, Fowler N, Dong C, Davis RE , Neelapu SS. Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. J Immunol 190(12):6681-93, 2013. e-Pub 2013. PMID: 23686488.
55. Cha SC, Qin H, Kannan S, Rawal S, Watkins LS, Baio FE, Wu W, Ong J, Wei J, Kwak B, Kim S, Popescu MS, Paick DS, Kim K, Luong A, Davis RE , Schroeder HW, Kwak LW, Neelapu SS. Nonstereotyped lymphoma B cell receptors recognize vimentin as a shared autoantigen. J Immunol 190(9):4887-98, 2013. e-Pub 2013. PMID: 23536634.
56. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE , Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121(20):4166-74, 2013. e-Pub 2013. PMID: 23564911.
57. Hailemichael Y, Dai Z, Jaffarzad N, Ye Y, Medina MA, Huang XF, Dorta-Estremera SM, Greeley NR, Nitti G, Peng W, Liu C, Lou Y, Wang Z, Ma W, Rabinovich B, Sowell RT, Schluns KS, Davis RE , Hwu P, Overwijk WW. Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nat Med 19(4):465-72, 2013. e-Pub 2013. PMID: 23455713.
58. Gu Z, Zhang F, Wang ZQ, Ma W, Davis RE , Wang Z. The p44/wdr77-dependent cellular proliferation process during lung development is reactivated in lung cancer. Oncogene 32(15):1888-900, 2013. e-Pub 2012. PMID: 22665061.
59. Zheng Y, Yang J, Qian J, Qiu P, Hanabuchi S, Lu Y, Wang Z, Liu Z, Li H, He J, Lin P, Weber D, Davis RE , Kwak L, Cai Z, Yi Q. PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia 27(3):702-10, 2013. e-Pub 2012. PMID: 22996336.
60. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, Zhang M, Cooper ZA, Frederick DT, Li Y, Zhang M, Joseph RW, Bernatchez C, Ekmekcioglu S, Grimm E, Radvanyi LG, Davis RE , Davies MA, Wargo JA, Hwu P, Lizée G. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res 18(19):5329-40, 2012. e-Pub 2012. PMID: 22850568.
61. Kuhn DJ, Berkova Z, Jones RJ, Woessner R, Bjorklund CC, Ma W, Davis RE , Lin P, Wang H, Madden TL, Wei C, Baladandayuthapani V, Wang M, Thomas SK, Shah JJ, Weber DM, Orlowski RZ. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 120(16):3260-70, 2012. e-Pub 2012. PMID: 22932796.
62. Gu Z, Gao S, Zhang F, Wang Z, Ma W, Davis RE , Wang Z. Protein arginine methyltransferase 5 is essential for growth of lung cancer cells. Biochem J 446(2):235-41, 2012. PMID: 22708516.
63. Lemoine M, Derenzini E, Buglio D, Medeiros LJ, Davis RE , Zhang J, Ji Y, Younes A. The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood 119(17):4017-25, 2012. e-Pub 2012. PMID: 22408261.
64. O'Connor C, Sheppard S, Hartline C, Huls H, Johnson M, Palla S, Maiti S, Ma W, Davis RE , Craig S, Champlin R, Wilson H, Cooper L. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma. Scientific Reports 2:249-260, 2012. PMID: 22355761.
65. Derenzini E, Lemoine M, Buglio D, Katayama H, Ji Y, Davis RE , Sen S, Younes A. The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma. Blood Cancer J 1(12):e46, 2011. e-Pub 2011. PMID: 22829094.
66. Annunziata CM, Hernandez L, Davis RE , Zingone A, Lamy L, Lam LT, Hurt EM, Shaffer AL, Kuehl WM, Staudt LM. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 117(2396):404, 2011. PMID: 21163924.
67. Bjorklund CC, Ma W, Wang ZQ, Davis RE , Kuhn DJ, Kornblau SM, Wang ML, Shah JJ, Orlowski RZ. Evidence of a role for activation of Wnt/{beta}-catenin signaling in the resistance of plasma cells to lenalidomide. J Biol Chem 286(11009):20, 2011. PMID: 21189262.
68. Davis RE , NgoVN*, Lenz G*, Tolar P, Young R, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang J, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM. Chronic active B cell receptor signaling in diffuse large B cell lymphoma. Nature 463:88-92, 2010. PMID: 20805315.
69. Ma W, Wang M, Wang ZQ, Sun L, Graber D, Matthews J, Champlin R, Yi Q, Orlowski RZ, Kwak LW, Weber DM, Thomas SK, Shah J, Kornblau S, Davis RE . Effect of Long-Term Storage in Trizol on Microarray-Based Gene Expression Profiling. Cancer Epidemiol Biomarkers Prev(19):2445-52, 2010. PMID: 20805315.
70. Rui L, Emre NCT, Kruhlak MJ, Chung H-J, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao Ho, Yang Y, Lamy L, Davis RE , Xiao W, Powell J, Maloney D, Thomas CJ, Möller P, Rosenwald A, Ott G, Muller-Hermelink HK, Savage K, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Weisenburger DD, Chan WC, Gascoyne RD, Levens D, Staudt LM. Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell 18:590-605, 2010. PMID: 21156283.
71. Coffey GP, Rajapaksa R, Liu R, Sharpe O, Kuo CC, Krauss SW, Sagi Y, Davis RE , Staudt LM, Sharman JP, Robinson WH, Levy S. Engagement of CD81 induces ezrin tyrosine phosphorylation and its cellular redistribution with filamentous actin. J Cell Sci 122(Pt 17):3137-44, 2009. e-Pub 2009. PMID: 19654214.
72. Meragelman TL, Scudiero DA, Davis RE , Staudt LM, McCloud TG, Cardellina JH, Shoemaker RH. Inhibitors of the NF-kappaB Activation Pathway from Cryptocarya rugulosa ( paragraph sign). J Nat Prod 72(3):336-9, 2009. e-Pub 2008. PMID: 19093800.
73. Lam LT, Davis RE , Ngo VN, Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, Staudt LM. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 105(52):20798-803, 2008. e-Pub 2008. PMID: 19104039.
74. Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE , Carty S, Lam LT, Shaffer AL, Xiao W, Powell J, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 105(36):13520-5, 2008. e-Pub 2008. PMID: 18765795.
75. Lam LT, Wright G, Davis RE , Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 111(7):3701-13, 2008. e-Pub 2007. PMID: 18160665.
76. Lenz G, Davis RE , Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao H, Xu W, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 319(5870):1676-9, 2008. e-Pub 2008. PMID: 18323416.
77. Bidère N, Ngo VN, Lee J, Collins C, Zheng L, Wan F, Davis RE , Lenz G, Anderson DE, Arnoult D, Vazquez A, Sakai K, Zhang J, Meng Z, Veenstra TD, Staudt LM, Lenardo MJ. Casein kinase 1alpha governs antigen-receptor-induced NF-kappaB activation and human lymphoma cell survival. Nature 458(7234):92-6, 2008. e-Pub 2008. PMID: 19118383.
78. Xie Y, Deng S, Thomas CJ, Liu Y, Zhang YQ, Rinderspacher A, Huang W, Gong G, Wyler M, Cayanis E, Aulner N, Többen U, Chung C, Pampou S, Southall N, Vidovic D, Schürer S, Branden L, Davis RE , Staudt LM, Inglese J, Austin CP, Landry DW, Smith DH, Auld DS. Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation. Bioorg Med Chem Lett 18(1):329-35, 2008. e-Pub 2007. PMID: 18024113.
79. Annunziata CM, Davis RE , Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD, Kuehl WM, Staudt LM. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2):115-30, 2007. PMID: 17692804.
80. Davis RE , Zhang YQ, Southall N, Staudt LM, Austin CP, Inglese J, Auld DS. A cell-based assay for IkappaBalpha stabilization using a two-color dual luciferase-based sensor. Assay Drug Dev Technol 5(1):85-103, 2007. PMID: 17355202.
81. Ngo VN, Davis RE *, Lamy L, Yu X, Zhao H, Lenz G, Lam L, Dave S, Yang L, Powell J, Staudt LM. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 441(7089):106-10, 2006. e-Pub 2006. PMID: 16572121.
82. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L, Lam LT, Davis RE , Staudt LM. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210:67-85, 2006. PMID: 16623765.
83. Song L, Zlobin A, Ghoshal P, Zhang Q, Houde C, Weijzen S, Jiang Q, Nacheva E, Yagan D, Davis E , Galiegue-Zouitina S, Catovsky D, Grogan T, Fisher RI, Miele L, Coignet LJ. Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas. Cancer Res 65(11):4554-61, 2005. PMID: 15930272.
84. Ho L, Davis RE , Conne B, Chappuis R, Berczy M, Mhawech P, Staudt LM, Schwaller J. MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-kappa B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood 105(7):2891-9, 2005. e-Pub 2004. PMID: 15598810.
85. Crowder C, Dahle Ø, Davis RE , Gabrielsen OS, Rudikoff S. PML mediates IFN-alpha-induced apoptosis in myeloma by regulating TRAIL induction. Blood 105(3):1280-7, 2005. e-Pub 2004. PMID: 15459016.
86. Lam LT, Davis RE , Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y, Wen D, Adams J, Dang L, Staudt LM. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 11(1):28-40, 2005. PMID: 15671525.
87. Rosenwald A, Chuang EY, Davis RE , Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM. Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104(5):1428-34, 2004. e-Pub 2004. PMID: 15138159.
88. Meffre E, Schaefer A, Wardemann H, Wilson P, Davis E , Nussenzweig MC. Surrogate light chain expressing human peripheral B cells produce self-reactive antibodies. J Exp Med 199(1):145-50, 2004. e-Pub 2003. PMID: 14699083.
89. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE , Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101(12):4944-51, 2003. e-Pub 2003. PMID: 12595313.
90. Kalaitzidis D, Davis RE , Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-kappaB signal transduction pathway. Oncogene 21(57):8759-68, 2002. PMID: 12483529.
91. Davis RE , Staudt LM. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr Opin Hematol 9(4):333-8, 2002. PMID: 12042708.
92. Shibata A, Parsonnet J, Longacre TA, Garcia MI, Puligandla B, Davis RE , Vogelman JH, Orentreich N, Habel LA. CagA status of Helicobacter pylori infection and p53 gene mutations in gastric adenocarcinoma. Carcinogenesis 23(3):419-24, 2002. PMID: 11895856.
93. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE , Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 194(11):1639-47, 2001. PMID: 11733578.
94. Davis RE , Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861-74, 2001. PMID: 11748286.
95. Lam LT, Pickeral OK, Peng AC, Rosenwald A, Hurt EM, Giltnane JM, Averett LM, Zhao H, Davis RE , Sathyamoorthy M, Wahl LM, Harris ED, Mikovits JA, Monks AP, Hollingshead MG, Sausville EA, Staudt LM. Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2(10):RESEARCH0041, 2001. e-Pub 2001. PMID: 11597333.
96. Meffre E, Davis E , Schiff C, Cunningham-Rundles C, Ivashkiv LB, Staudt LM, Young JW, Nussenzweig MC. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 1(3):207-13, 2000. PMID: 10973277.
97. Alizadeh AA, Eisen MB, Davis RE , Ma C, Lossos I, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr. J, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Levy R, Wilson W, Grever M, Byrd J, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503-11, 2000. PMID: 10676951.
98. Alizadeh A, Eisen M, Davis RE , Ma C, Sabet H, Tran T, Powell JI, Yang L, Marti G, Moore DT, Hudson JR, Chan WC, Greiner T, Weisenburger D, Armitage JO, Lossos I, Levy R, Botstein, Brown PO, Staudt LM. The Lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb Symp Quant Biol 64:71-8, 1999. PMID: 11232339.
99. Advani R, Visani G, Milligan D, Saba H, Tallman M, Rowe JM, Wiernik PH, Ramek J, Dugan K, Lum B, Villena J, Davis E , Paietta E, Litchman M, Covelli A, Sikic B, Greenberg P. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol 457:47-56, 1999. PMID: 10500779.
100. Blankenberg FG, Katsikis PD, Tait JF, Davis RE , Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Strauss HW. Imaging of apoptosis (programmed cell death) with 99mTc annexin V. J Nucl Med 40(1):184-91, 1999. PMID: 9935075.
101. Davis RE , Mysore V, Browning JC, Hsieh JC, Lu QA, Katsikis PD. In situ staining for poly(ADP-ribose) polymerase activity using an NAD analogue. J Histochem Cytochem 46(11):1279-89, 1998. PMID: 9774627.
102. Davis RE , Greenberg PL. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res 22(9):767-77, 1998. PMID: 9716007.
103. Blankenberg FG, Katsikis PD, Tait JF, Davis RE , Naumovski L, Ohtsuki K, Kopiwoda S, Abrams MJ, Darkes M, Robbins RC, Maecker HT, Strauss HW. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A 95(11):6349-54, 1998. PMID: 9600968.
104. Hausdorff J, Davis E , Long G, Hoppe R, van der Pas M, Lassman C, Kamel O, Jacobs C. Non-Hodgkin's lymphoma of the paranasal sinuses: clinical and pathological features, and response to combined-modality therapy. Cancer J Sci Am 3(5):303-11, 1997. PMID: 9327155.
105. Davis RE , Stenberg PE, Levin J, Beckstead JH. Localization of megakaryocytes in normal mice and following administration of platelet antiserum, 5-fluorouracil, or radiostrontium: evidence for the site of platelet production. Exp Hematol 25(7):638-48, 1997. PMID: 9216740.
106. Soslow RA, Davis RE , Warnke RA, Cleary ML, Kamel OW. True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood 87(12):5207-12, 1996. PMID: 8652834.
107. Arber D, Kamel O, van de Rijn M, Davis RE , Medeiros LJ, Jaffe ES, Weiss LM. Frequent presence of the Epstein-Barr virus in inflammatory pseudotumor. Hum Pathol 26(10):1093-8, 1995. PMID: 7557942.
108. Davis RE , Longacre TA, Cornbleet PJ. Hematogones in the bone marrow of adults. Immunophenotypic features, clinical settings, and differential diagnosis. Am J Clin Pathol 102(2):202-11, 1994. PMID: 8042590.
109. Davis E , Corash L, Stenberg P, Levin J. Histologic studies of splenic megakaryocytes after bone marrow ablation with strontium 90. J Lab Clin Med 120(5):767-77, 1992. PMID: 1431506.
110. Davis RE , Smoller BR. T lymphocytes expressing HECA-452 epitope are present in cutaneous acute graft-versus-host disease and erythema multiforme, but not in acute graft-versus-host disease in gut organs. Am J Pathol 141(3):691-8, 1992. PMID: 1381561.
111. Davis RE , Warnke RA, Dorfman RF. Inflammatory pseudotumor of lymph nodes. Additional observations and evidence for an inflammatory etiology. Am J Surg Pathol 15(8):744-756, 1991. PMID: 2069212.
112. Kamel OW, Lebrun DP, Davis RE , Berry GJ, Warnke RA. Growth fraction estimation of malignant lymphomas in formalin fixed paraffin embedded tissue using anti-PCNA/Cyclin 19A2: correlation with Ki-67 labeling. Am J Pathol 138(6):1471-1477, 1991. PMID: 1675840.
113. Davis RE , Warnke RA, Dorfman RF, Cleary ML. Utility of molecular genetic analysis for the diagnosis of neoplasia in morphologically and immunophenotypically equivocal hematolymphoid lesions. Cancer 67(11):2890-9, 1991. PMID: 2025855.
114. Kemper CA, Davis RE , Deresinski SC, Dorfmann RF. Inflammatory pseudotumor of intra-abdominal lymph nodes manifesting as recurrent fever of unknown origin: a case report. Am J Med 90(4):519-23, 1991. PMID: 2012094.
115. Davis RE , Dorfman RF, Warnke RA. Primary large-cell lymphoma of the thymus: a diffuse B-cell neoplasm presenting as primary mediastinal lymphoma. Hum Pathol 21(12):1262-8, 1990. PMID: 2249839.
116. Davis E , Corash L, Baker G, Mok Y, Hill RJ, Levin J. Splenic thrombopoiesis after bone marrow ablation with radiostrontium: a murine model. J Lab Clin Med 116(6):879-88, 1990. PMID: 2246562.
117. Rawal BD, Davis RE , Busch MP, Vyas GN. Dual reduction in the immunologic and infectious complications of transfusion by filtration/removal of leukocytes from donor blood soon after collection. Transfus Med Rev 4(4 Suppl 1):36-41, 1990. PMID: 2134639.
118. Holtzman DM, Davis RE , Greco CM. Lumbosacral plexopathy secondary to perirectal abscess in a patient with HIV infection. Neurology 39(10):1400-1, 1989. PMID: 2552352.
119. Houck JA, Davis RE , Sharma HM. Thyroid-stimulating immunoglobulin as a cause of recurrent intrauterine fetal death. Obstet Gynecol 71(6 Pt 2):1018-9, 1988. PMID: 2897651.

Invited Articles

1. Fowler N, Davis E. Targeting B-cell receptor signaling: changing the paradigm. Hematology Am Soc Hematol Educ Program 2013:553-60, 2013. PMID: 24319231.

Editorials

1. Davis RE, Westin JR. Vive la résistance: stem cells in mantle cell lymphoma. Leuk Lymphoma 52:944-5, 2011. PMID: 21463111.
2. Davis RE. Commentary: In vitro chemosensitivity testing in the genomic era. Leuk Lymphoma 49(2040), 2008. PMID: 19021046.
3. Dunleavy K, Davis RE, Landgren O, Staudt LM, Wilson WH. BCL-6 and rituximab in diffuse large B-cell lymphoma: where are we?. Blood 109:843-4, 2007. PMID: 1721065.

Book Chapters

1. Davis RE. Genomic analysis of B-cell lymphomas. In: Lymphoma: Diagnosis and Treatment. Springer, 2013.